Research map: Understanding Biased Signaling and Small-Molecule Binding for Treatment of Type 2 Diabetes Mellitus and Obesity at the Glucagon-Like Peptide-1 Receptor (GLP-1R) Based on Molecular Dynamics Simulations

Back to the article

Papers in this map

  1. Comparison of simple potential functions for simulating liquid water · William L. Jorgensen · 1983 · 42955 citations · Cited by this paper
  2. Small Molecule Insulin Sensitisers: New Leads and Targets for Next-Generation Insulin Sensitising Strategies · 2026 · Related
  3. GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers · M Abraham · 2015 · 28412 citations · Cited by this paper
  4. Alisols A-C and their acetate derivatives: a review of natural occurrence, pharmacology, semisynthesis, pharmacokinetics, and metabolism · 2026 · Related
  5. Canonical dynamics: Equilibrium phase-space distributions · William Graham Hoover · 1985 · 23956 citations · Cited by this paper
  6. Investigation of reported small molecule P2Y6 receptor antagonists · 2026 · Related
  7. A molecular dynamics method for simulations in the canonical ensemble · Shūichi Nosé · 1984 · 10282 citations · Cited by this paper
  8. Discovery of 3-(N-phenylsulfamoyl)-l-phenylalanine derivatives as novel and orally available LAT1-selective inhibitors · 2026 · Related
  9. CHARMM‐GUI: A web‐based graphical user interface for CHARMM · Sunhwan Jo · 2008 · 10149 citations · Cited by this paper
  10. From lipophilicity windows to decision-grade antibacterial design: the next translational step for coumarin amphiphiles · 2026 · Related
  11. CHARMM36m: an improved force field for folded and intrinsically disordered proteins · Jing Huang · 2016 · 8030 citations · Cited by this paper
  12. Inactivation of ornithine aminotransferase by (1R,4S)-4-Amino-3-(trifluoromethyl)cyclopent-2-ene-1-carboxylic acid via a stable quinonoid intermediate · 2026 · Related
  13. Update of the CHARMM All-Atom Additive Force Field for Lipids: Validation on Six Lipid Types · Jeffery B. Klauda · 2010 · 4853 citations · Cited by this paper
  14. Characterization of beddomeilactone amide as bacterial DNA gyrase inhibitor: in vitro evaluation and computational insights · 2026 · Related
  15. CHARMM-GUI Input Generator for NAMD, GROMACS, AMBER, OpenMM, and CHARMM/OpenMM Simulations Using the CHARMM36 Additive Force Field · Jumin Lee · 2015 · 4526 citations · Cited by this paper
  16. Synthesis and antihepatoma activity of dimeric 1-O-acetylbritannilactone derivatives · 2026 · Related
  17. CHARMM-GUI Membrane Builder toward realistic biological membrane simulations · Emilia L. Wu · 2014 · 2907 citations · Cited by this paper
  18. Unrevealing the Role of Flavonoids in Mitigation of Non-Alcoholic Fatty Liver Disease · 2026 · Related
  19. Discovery of the Once-Weekly Glucagon-Like Peptide-1 (GLP-1) Analogue Semaglutide · Jesper F. Lau · 2015 · 1093 citations · Cited by this paper
  20. Development and evaluation of mitochondria-targeted caseinolytic protease (ClpP) agonist chemical probes in in vitro breast cancer models · 2026 · Related
  21. Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein · Yan Zhang · 2017 · 604 citations · Cited by this paper
  22. Phase-plate cryo-EM structure of a class B GPCR–G-protein complex · Yi-Lynn Liang · 2017 · 487 citations · Cited by this paper
  23. Phase-plate cryo-EM structure of a biased agonist-bound human GLP-1 receptor–Gs complex · Yi-Lynn Liang · 2018 · 345 citations · Cited by this paper
  24. Differential GLP-1R Binding and Activation by Peptide and Non-peptide Agonists · Xin Zhang · 2020 · 239 citations · Cited by this paper
  25. Structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist · Takahiro Kawai · 2020 · 226 citations · Cited by this paper
  26. A Small-Molecule Oral Agonist of the Human Glucagon-like Peptide-1 Receptor · David A. Griffith · 2022 · 174 citations · Cited by this paper
  27. Structural insights into multiplexed pharmacological actions of tirzepatide and peptide 20 at the GIP, GLP-1 or glucagon receptors · Fenghui Zhao · 2022 · 150 citations · Cited by this paper
  28. GIPR/GLP-1R dual agonist therapies for diabetes and weight loss—chemistry, physiology, and clinical applications · Jonathan E. Campbell · 2023 · 149 citations · Cited by this paper
  29. Extending the Structural View of Class B GPCRs · Chris de Graaf · 2017 · 134 citations · Cited by this paper
  30. Toward a Structural Understanding of Class B GPCR Peptide Binding and Activation · Yi-Lynn Liang · 2020 · 128 citations · Cited by this paper
  31. Structural determinants of dual incretin receptor agonism by tirzepatide · Bingfa Sun · 2022 · 127 citations · Cited by this paper
  32. Structural perspective of class B1 GPCR signaling · Zhaotong Cong · 2022 · 86 citations · Cited by this paper
  33. Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes · Xin Zhang · 2021 · 76 citations · Cited by this paper
  34. New Insights into the Structure and Function of Class B1 GPCRs · Brian P. Cary · 2022 · 75 citations · Cited by this paper
  35. Structural and functional diversity among agonist-bound states of the GLP-1 receptor · Brian P. Cary · 2021 · 64 citations · Cited by this paper
  36. Structural insights into the activation of GLP-1R by a small molecule agonist · Honglei Ma · 2020 · 59 citations · Cited by this paper
  37. The effect of GLP-1R agonists on the medical triad of obesity, diabetes, and cancer · Shahad Sabaawi Ibrahim · 2024 · 52 citations · Cited by this paper
  38. Structural analysis of the dual agonism at GLP-1R and GCGR · Yang Li · 2023 · 42 citations · Cited by this paper
  39. Structural pharmacology and mechanisms of GLP-1R signaling · Qingtong Zhou · 2025 · 40 citations · Cited by this paper

Source: OpenAlex (CC0)